The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

February 8, 2022 • By Residents from the RheumMadness Leadership Team: Michael Macklin, MD, PharmD; Ben Kellogg, MD; Lauren He, MD; & David Leverenz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Editor’s note: RheumMadness is the place for everyone crazy about rheumatology to connect, collaborate, compete and learn together. During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports for each concept team. These reports are written by rheumatology fellows from 13 programs throughout the U.S.

You Might Also Like
  • Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report
Explore This Issue
May 2022

Don’t forget to submit your RheumMadness 2022 bracket by March 25. The more your picks match those of our Blue Ribbon Panel of rheumatologists, the more points you get. Learn more about the panel and how the brackets work online.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Connect with RheumMadness by subscribing to the podcast and joining the conversation on Twitter, #RheumMadness. Learn more on the RheumMadness website.

Region: Cells

Team: Pim Kinases

Michael Jordan didn’t just dominate the basketball world of the 1990s—he also tried his hand at baseball. In this team’s base article by Maney et al., Pim kinases lace up their Air Jordans and try to “be like Mike,” showing promise as the next great two-sport athlete in both oncology and rheumatology.1

There are three Pim kinase subtypes: Pim-1, Pim-2 and Pim-3. These kinases are considered oncoproteins because, when overactive, they increase cell survival, proliferation and migration, and their overexpression is associated with worse clinical outcomes in cancer. Thus, oncologists are already investigating the anti-tumor effects of Pim kinase inhibitors. However, cancer cells are not the only cells that proliferate out of control due to Pim kinases. It turns out Pim kinases are downstream of the interleukin (IL) 6/STAT3 inflammatory pathway, and a growing body of literature shows Pim kinases influence T cell differentiation and synovial fibroblast function in rheumatoid arthritis (RA).1,2

The base article for this team demonstrates how Pim kinases contribute to RA pathogenesis, explores the therapeutic potential of Pim kinase inhibition in RA and tantalizes readers with a possible precision medicine approach to identify patients who may benefit from this therapy.1 Using the Newcastle Early Arthritis Cohort (NEAC), the authors found increased Pim-1 expression in CD4+ T cells and other T cells in patients with early RA compared with patients with non-RA rheumatic diseases (e.g., psoriatic arthritis, other SpA, SLE and gout). This finding wasn’t just in peripheral blood; it also occurred in synovial biopsies of patients with early RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: cells, Pim kinase, Rheumatoid Arthritis (RA), RheumMadnessIssue: May 2022

You Might Also Like:
  • Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report
  • Back to Basics: RheumMadness 2022 Increasing ANA Positivity Scouting Report

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)